therapeut
recombin
human
catalas
rhcat
quench
infectioninduc
reactiv
oxygen
speci
ro
therebi
allevi
associ
tissu
damag
although
intranas
rout
effici
deliv
nativ
rhcat
lung
therapeut
effect
limit
rapid
elimin
blood
studi
modifi
rhcat
activ
polym
polyethylen
glycol
monomethyl
ether
peg
analyz
pharmacokinet
pegyl
rhcat
mice
high
tetrapegyl
ratio
pegyl
prolong
halflif
rhcat
serum
vs
min
nativ
rhcat
protect
effect
pegrhcat
investig
mous
model
influenza
viru
associ
pneumonia
pegrhcat
effect
deliv
nativ
rhcat
associ
higher
surviv
ratio
less
extens
lung
injuri
reduc
ro
level
lower
viral
replic
collect
find
indic
pegyl
enhanc
therapeut
efficaci
nativ
rhcat
suggest
pegyl
rhcat
may
repres
novel
complement
therapi
influenzainduc
pneumonia
reactiv
oxygen
speci
ro
implic
pathogenesi
myriad
diseas
rang
cancer
cerutti
atherosclerosi
halliwel
gutteridg
alzheim
diseas
simonian
coyl
human
immunodefici
viru
infect
deng
et
al
although
ro
function
benefici
compon
immun
respons
unregul
excess
ro
toxic
induc
irrepar
damag
cellular
membran
protein
nucleic
acid
normal
physiolog
condit
antioxid
enzym
help
maintain
balanc
ro
function
interact
lead
interest
gener
antioxid
therapeut
agent
rosmedi
injuri
diseas
catalas
cat
one
key
antioxid
enzym
mammalian
system
cat
work
catalyz
decomposit
h
molecular
oxygen
water
lv
et
al
ogbeyalu
et
al
brian
cat
play
import
role
develop
toler
oxid
stress
process
defin
protect
sever
patholog
condit
allergi
yoshimaru
et
al
atherosclerosi
kudchodkar
et
al
ischemia
hanawa
et
al
chronic
granulomat
yu
et
al
metastat
tumor
progress
nishikawa
et
al
hyoudou
et
al
age
brownborg
rakoczi
potenti
catalas
therapeut
agent
explor
mani
differ
diseas
mani
differ
form
includ
gene
therapi
guy
et
al
recombin
catalas
yabe
et
al
well
decad
previou
studi
found
inhal
nativ
recombin
human
catalas
rhcat
elicit
protect
effect
mice
influenzaassoci
pneumonia
shi
et
al
accord
global
estim
gener
world
health
organ
million
case
pneumonia
diagnos
everi
year
approxim
four
million
case
end
death
account
total
mortal
worldwid
recent
emerg
sever
acut
respiratori
syndrom
sar
associ
coronaviru
avian
influenza
viru
pandem
influenza
viru
serv
highlight
respiratori
virus
import
caus
agent
sever
pneumonia
nonetheless
current
batteri
antivir
avail
clinic
practic
treatment
pneumonia
limit
ruuskanen
et
al
rudan
et
al
continu
pandem
threat
circul
virus
make
identif
develop
novel
therapeut
strategi
especi
treatment
influenza
urgent
matter
derek
pneumonia
sever
acut
lung
injuri
often
occur
infect
influenza
viru
viru
invas
bronchi
andor
alveoli
lung
destroy
structur
lead
drastic
reduct
air
space
essenti
oxygenco
exchang
hurt
et
al
immun
respons
viru
manifest
increas
vasodil
leakag
leukocyt
neutrophil
lung
tissu
ultim
result
lifethreaten
pulmonari
edema
congest
studi
identifi
mechan
underli
cell
death
associ
influenzainduc
pneumonia
implic
ro
promot
extent
lung
injuri
respir
compromis
gangehei
et
al
case
et
al
nakamura
et
al
thu
theoriz
quench
ro
level
might
promis
strategi
allevi
sever
viral
pneumonia
despit
success
recent
develop
inhal
nativ
rhcatboth
target
deliveri
site
infect
produc
protect
effect
mice
influenza
viral
pneumonia
shi
et
al
therapeut
effect
limit
rapid
elimin
circul
therefor
present
studi
rhcat
conjug
activ
polyethylen
attempt
extend
halflif
rhcat
enhanc
therapeut
effect
influenzainduc
pneumonia
imprint
control
region
icr
mice
weigh
g
purchas
shanghai
slacca
laboratori
anim
co
ltd
shanghai
china
mice
rat
hous
specif
pathogenfre
condit
feder
licens
biosafeti
level
anim
facil
anim
given
free
access
steril
water
standard
ratmous
chow
experiment
protocol
approv
anim
experi
committe
fudan
univers
shanghai
china
influenza
viru
strain
suppli
shanghai
center
diseas
control
prevent
shanghai
china
store
aliquot
experi
aliquot
thaw
ensur
use
fresh
prepar
michel
et
al
pegyl
rhcat
sigmaaldrich
st
loui
mo
usa
polym
activ
cyanur
chlorid
coupl
rhcat
use
previous
describ
protocol
baysal
uslan
briefli
reaction
mixtur
dilut
mm
na
hpo
load
onto
sephacryl
gel
filtrat
column
ge
healthcar
uppsala
sweden
equilibr
buffer
mm
phosphat
buffer
ph
use
akta
purifi
protein
purif
system
ge
healthcar
fraction
correspond
protein
peak
collect
analysi
sdspage
confirm
pegyl
protein
dissolv
salin
solut
steril
filtrat
pore
size
dilut
work
concentr
subsequ
anim
administr
spraguedawley
rat
randomli
divid
three
treatment
group
n
rhcat
pegrhcat
salinetr
control
treatment
consist
singl
intranas
deliveri
rhcat
pegrhcat
kukg
equal
volum
salin
blood
sampl
ml
drawn
via
retroorbit
venou
plexu
vial
contain
select
posttreat
time
point
min
sampl
allow
clot
min
serum
collect
centrifug
min
serum
cat
activ
measur
use
catalas
activ
assay
kit
jiancheng
bioengin
institut
nanj
china
follow
manufactur
instruct
icr
mice
randomli
divid
four
treatment
group
virusinfect
nativ
rhcat
virusinfect
pegrhcat
virusinfect
salinetr
control
uninfect
salinetr
control
rhcat
nativ
pegyl
form
prepar
administr
previous
describ
shi
et
al
mice
except
uninfect
salinetr
control
group
anesthet
isofluran
infect
influenza
viru
via
intranas
inocul
tcid
mice
receiv
groupappropri
treatment
influenza
infect
treatment
mice
group
anesthet
twice
daili
administ
one
follow
solut
intranas
rout
kukg
nativ
rhcat
solut
kukg
pegrhcat
solut
salin
uninfect
virusinfect
control
group
virusinfect
mice
randomli
divid
three
group
nativerhcat
pegyl
rhcat
untreat
control
treatment
administ
describ
seven
day
eighth
day
mice
began
monitor
surviv
next
six
day
surviv
analysi
curv
gener
plot
number
survivor
divid
total
number
mice
group
express
percentag
mice
surviv
data
plot
day
infect
sinc
mortal
occur
beyond
time
point
control
uninfect
mice
treat
salin
viral
pneumonia
mice
treat
rhcat
pegrhcat
four
day
mice
sacrif
exsanguin
tissu
harvest
suspend
pbsbuffer
formalin
excis
lung
preserv
paraffin
block
tissu
section
cut
place
glass
slide
stain
hematoxylin
eosin
microscop
analysi
carri
three
separ
pathologist
blind
variou
experiment
treatment
tissu
inflamm
score
assign
analyz
section
lung
use
mean
score
obtain
six
separ
random
field
per
tissu
section
score
assign
accord
percentag
lung
involv
follow
viral
load
measur
hemagglutin
assay
ha
titer
previous
describ
briefli
mous
lung
tissu
sampl
mice
group
pool
homogen
ml
steril
normal
salin
aliquot
whole
lung
homogen
twofold
serial
dilut
homogen
place
well
vshape
microtit
plate
sampl
cover
freshli
prepar
chicken
blood
corpuscl
incub
room
temperatur
h
control
normal
salin
cover
chicken
blood
corpuscl
ha
titer
express
reciproc
dilut
sampl
last
well
complet
hemagglutin
detect
malondialdehyd
mda
antioxid
enzym
content
total
antioxid
statu
ta
mous
lung
homogen
freshli
prepar
describ
ta
content
mda
superoxid
dismutas
sod
cat
determin
use
commerci
avail
assay
kit
no
respect
jiancheng
bioengin
institut
statist
analys
perform
use
spss
softwar
version
spss
inc
chicago
il
usa
data
present
unless
otherwis
indic
intergroup
comparison
carri
oneway
anova
twotail
student
test
p
valu
less
consid
statist
signific
pegyl
rhcat
carri
describ
materi
method
achiev
high
ratio
tetrapegyl
protein
total
protein
low
percentag
pegyl
protein
indic
high
pressur
size
exclus
chromatograph
analysi
fig
tabl
fraction
pegyl
rhcat
kda
sdspage
subunit
tetrapegyl
protein
separ
fraction
unmodifi
protein
kda
sdspage
gel
filtrat
chromatographi
current
reaction
purif
condit
activ
nativ
pegyl
rhcat
remain
well
fig
rel
activ
pegyl
rhcat
similar
nativ
rhcat
vs
kumg
respect
indic
peg
modif
follow
purif
affect
protein
function
signific
differ
cat
activ
among
three
rat
treatment
group
prior
intranas
administr
variou
treatment
time
min
pegrhcat
vs
nativ
rhcat
vs
untreat
control
shown
fig
cat
activ
peak
pegand
nativ
rhcat
group
uml
min
posttreat
nativ
rhcattreat
group
serum
cat
activ
rapidli
decreas
min
time
point
halflif
determin
min
pegyl
rhcat
also
decreas
min
time
point
significantli
reduc
rate
indic
peg
modif
produc
serum
stabil
halflif
pegrhcat
min
repres
signific
improv
nativ
form
mice
infect
influenza
viru
treat
nativ
rhcat
pegrhcat
seven
day
shown
sinc
extent
pulmonari
injuri
shown
associ
morbid
influenza
viru
strain
hurt
et
al
abil
pegrhcat
protect
lung
tissu
investig
histopatholog
analysi
mice
influenza
pneumonia
reveal
treatment
either
nativ
pegyl
rhcat
led
reduc
fig
pegyl
markedli
prolong
serum
halflif
rhcat
rat
rat
rat
group
intranas
administ
kukg
pegrhcat
fill
diamond
nativ
rhcat
open
circl
left
untreat
control
fill
upright
triangl
blood
sampl
collect
indic
time
point
cat
activ
measur
fig
pegyl
rhcat
significantli
improv
surviv
rate
mice
viral
pneumonia
day
group
mice
group
infect
intranas
influenza
viru
tcid
dose
day
postinfect
kukg
pegrhcat
black
circl
nativ
rhcat
multipl
sign
distil
salin
control
black
squar
administ
intranas
twice
daili
day
treatment
termin
ratio
survivorstot
number
mice
day
denot
rightsid
terminu
surviv
curv
infiltr
inflammatori
cell
less
extens
interstiti
pneumonia
bronchiol
obvious
diminish
tissu
inflamm
score
day
postinfect
vs
viru
control
mice
patholog
analysi
lung
infect
mice
show
treatment
either
nativ
pegyl
rhcat
caus
mark
reduct
tissu
injuri
mononuclear
cell
infiltr
hemorrhag
pulmonari
edema
well
significantli
reduc
tissu
inflamm
score
nativ
form
pegyl
form
compar
viru
control
mice
postinfect
day
viru
control
group
area
increas
tissu
consolid
vascular
hemorrhag
detect
fig
rhcattreat
mice
fig
area
tissu
consolid
hemorrhag
less
numer
decreas
size
less
confluent
viru
control
mice
pegrhcat
produc
effect
nativ
rhcat
greater
extent
indic
pegrhcat
superior
protect
abil
moreov
histopatholog
find
group
correspond
mortal
rate
observ
treatment
type
fig
ha
measur
method
employ
determin
effect
differ
rhcat
form
viral
burden
influenza
viru
mice
treatment
either
pegyl
rhcat
nativ
form
led
decreas
amount
viru
lung
day
postinfect
fig
viru
detect
blood
sampl
uninfect
salin
control
group
indic
influenza
viru
obtain
extraexperiment
mean
studi
popul
experiment
infect
mice
show
obviou
viral
titer
compar
viru
control
mice
infect
untreat
ha
titer
treatment
either
nativ
rhcat
pegrhcat
significantli
inhibit
viru
evidenc
reduc
ha
titer
moreov
pegyl
form
much
effect
nativ
form
lower
viral
burden
mice
influenza
pneumonia
pegyl
rhcat
administr
restor
balanc
antioxid
system
compon
lung
mice
influenza
pneumonia
sinc
copiou
amount
viru
induc
excess
oxid
respons
subsequ
exhaust
antioxid
pool
destroy
redox
balanc
level
key
antioxid
enzym
evalu
mice
influenza
pneumonia
rhcat
treatment
malondialdehyd
product
lipid
peroxid
often
present
tissu
oxid
injuri
expect
level
mda
significantli
increas
mice
influenza
pneumonia
compar
uninfect
salin
control
mice
howev
treatment
either
nativ
rhcat
pegrhcat
led
signific
reduct
mda
level
vs
untreat
viru
control
group
respect
moreov
pegyl
form
abl
reduc
mda
level
greater
extent
nativ
form
bring
much
closer
level
detect
uninfect
control
fig
cat
sod
consid
key
antioxid
enzym
antioxid
defens
system
activ
cat
sod
found
significantli
decreas
untreat
mice
influenza
pneumonia
find
indic
natur
immun
respons
ro
burst
induc
influenza
viru
invas
exhaust
enzym
pool
antioxid
system
treatment
either
pegyl
rhcat
nativ
rhcat
produc
rapid
increas
cat
fig
sod
fig
level
lung
tissu
find
suggest
augment
natur
cat
pool
rhcat
might
help
restor
redox
balanc
condit
viral
pneumonia
moreov
pegyl
form
rhcat
produc
significantli
robust
increas
cat
sod
level
nativ
form
measur
total
antioxid
statu
possibl
indirectli
estim
level
nonenzymat
antioxid
molecul
untreat
mice
influenza
pneumonia
show
significantli
reduc
ta
compar
uninfect
control
mice
fig
reduct
found
revers
respons
treatment
either
rhcat
pegyl
rhcat
pegyl
form
produc
robust
therapeut
effect
vs
nativ
rhcat
taken
togeth
data
indic
pegrhcat
administr
might
repres
effect
therapeut
agent
restor
compon
antioxid
system
inhibit
detriment
product
mda
factor
implic
high
morbid
mortal
influenza
viru
infect
includ
robust
cytokin
product
cytokin
storm
excess
inflammatori
infiltr
extens
virusinduc
tissu
destruct
date
antivir
drug
approv
treatment
pneumonia
wong
yuen
despit
success
develop
sever
new
antivir
agent
oseltamivir
ribavirin
pandem
threat
influenza
high
risk
mortal
persist
due
problem
relat
druginduc
advers
effect
emerg
resist
virus
rapid
loss
drug
efficaci
relat
serotyp
variat
thu
novel
therapeut
strategi
base
specif
manipul
viru
host
molecular
pathway
urgent
need
find
previou
current
studi
describ
novel
uniqu
strategi
allevi
viral
pneumonia
augment
avail
pool
cat
antioxid
enzym
proper
administr
via
intranas
rout
key
achiev
target
deliveri
lung
optim
potenti
therapeut
effect
requir
base
upon
short
halflif
origin
design
rhcat
nativ
form
preclud
usual
deliveri
rout
intraven
subcutan
periton
intranas
administr
nativ
rhcat
form
capabl
elicit
protect
effect
influenza
viru
pneumonia
mice
necessari
extend
halflif
rhcat
achiev
optim
therapeut
effect
catalas
macromolecular
kda
import
factor
serum
clearanc
catalas
degrad
serum
proteas
hepat
uptak
lowmolecularweight
peg
molecul
often
chosen
conjug
catalas
obvious
hinder
clearanc
rate
hanawa
et
al
yabe
et
al
therefor
present
studi
modifi
rhcat
activ
yshape
prolong
halflif
fivefold
nativ
rhcat
min
furthermor
therapeut
effect
rhcat
also
significantli
enhanc
peg
modif
base
protect
effect
observ
mice
influenza
pneumonia
hypothes
rhcat
may
influenc
multipl
pathogenesisrel
pathway
diseas
condit
first
excess
ro
burst
induc
viru
infect
recogn
key
factor
lung
damag
immun
respons
rapidli
exhaust
pool
avail
antioxid
evidenc
low
level
cat
sod
immediateearli
stage
sever
pathogen
infect
augment
natur
antioxid
pool
recombin
cat
promot
system
abil
elimin
excess
ro
help
restor
redox
balanc
inde
intranas
administr
pegrhcat
help
resolv
influenzainduc
perturb
mda
cat
sod
ta
mice
viral
pneumonia
manner
presum
pegrhcat
therapi
may
downregul
ro
therebi
help
allevi
destruct
lung
tissu
promot
surviv
second
influenza
invas
known
frequent
stimul
excess
immun
respons
accompani
robust
infiltr
inflammationrel
cell
monocyt
site
infect
persist
releas
inflammatori
factor
caus
signific
damag
underli
tissu
compromis
pulmonari
function
condit
excess
amount
ro
macrophageexpress
signal
molecul
activ
activ
induc
express
sever
chemokin
proinflammatori
cytokin
turn
recruit
peripher
inflammationrel
cell
virusinfect
organ
snelgrov
et
al
rosenblum
et
al
augment
antioxid
pool
recombin
cat
excess
ro
may
elimin
therebi
help
quell
macrophagemedi
process
apoptosi
rhcatmedi
clearanc
ro
may
also
help
halt
massiv
influx
immunomodulatori
cell
observ
histopatholog
analys
pulmonari
tissu
pegrhcattr
mice
influenza
pneumonia
third
viru
clearanc
initi
innat
immun
system
depend
upon
adapt
immun
process
complet
rosmedi
tissu
injuri
sever
infect
disrupt
normal
cell
develop
therebi
impair
adapt
immun
respons
inhibit
clearanc
influenza
infect
case
et
al
imai
et
al
studi
untreat
mice
influenza
pneumonia
present
atrophi
thymu
spleen
day
postinfect
data
shown
structur
destruct
immun
organ
function
consequ
immun
system
impair
matur
adapt
immun
cell
presum
hinder
effect
viru
clearanc
therapeut
administr
rhcat
howev
lower
viral
load
possibl
result
excess
ro
elimin
would
decreas
destruct
immunerel
organ
help
restor
specif
adapt
immun
respons
summari
pegyl
prolong
circulatori
halflif
rhcat
improv
therapeut
efficaci
pegyl
rhcat
may
repres
novel
adjuv
therapi
promot
efficaci
establish
therapeut
antivir
drug
promot
recoveri
surviv
viral
pneumonia
